Free Risdiplam for SMA patients to be made available in all districts

The government has announced a major expansion of free Risdiplam access for patients with spinal muscular atrophy, or SMA. Instead of requiring families to collect medicine from only two government medical colleges, it plans to provide the drug through Medical colleges in all districts. The aim is easier access, steadier treatment, and less pressure on families.

The medicine will be supplied through the Paediatrics departments of all Medical colleges. The Additional Chief Secretary (Health) will coordinate the initiative. This arrangement is designed to reduce long journeys and make it easier for patients to continue receiving their medicine near home.

Currently, free Risdiplam is available only through SMA clinics at the Thiruvananthapuram and Kozhikode Government Medical colleges. It is also limited to patients up to 12 years old. The government has begun steps to remove that restriction and extend free treatment to all eligible patients, regardless of age.

Risdiplam is a prescription medicine used to treat spinal muscular atrophy, or SMA. SMA is a genetic neuromuscular disease in which motor nerve cells become damaged or lost, causing progressive muscle weakness. It can affect movement, breathing, swallowing, and other everyday functions. These medical details are established knowledge; the article itself focuses on access rather than explaining the disease.

Risdiplam works by increasing production of survival motor neuron protein, which helps motor nerve cells function. By supporting these cells, the medicine can help preserve or improve muscle function in people with SMA. It is taken regularly, so continued access matters. The article calls it free medication for SMA patients and describes the need for continuity of care.

The government currently distributes Risdiplam through SMA clinics at two Government Medical colleges. It plans to make the medicine available through Paediatrics departments in Medical colleges across all districts. This should bring treatment closer to families and reduce travel-related hardship.

The distribution network is planned to expand across all districts. At present, free Risdiplam is available only through SMA clinics at the Thiruvananthapuram and Kozhikode Government Medical colleges. The new plan will make the medicine available through Medical colleges in every district, creating a much broader local access system.

For example, a family that now travels to one of those two cities could collect the medicine through a nearer Medical college. The Paediatrics department at each Medical college is expected to provide it. The Additional Chief Secretary (Health) will coordinate the rollout, helping organise the decentralised programme across the state.

This is a shift from two specialised distribution points to a district-wide network. The government says the change should make treatment easier to reach and support continuity of care. It also hopes the SMA model can later support families affected by other rare diseases and children with chronic illnesses.

Providing Risdiplam through Medical colleges in every district could greatly reduce the distance families travel to obtain treatment. The article says parents of children with SMA currently face considerable distress and financial pressure because they must travel long distances. A nearer collection point could make medicine access simpler and less costly.

For example, a family could visit the Paediatrics department of its district Medical college instead of travelling to the SMA clinic in Thiruvananthapuram or Kozhikode. The key mechanism is decentralised distribution. More Medical colleges would share responsibility for supplying the drug, making collection less dependent on two locations.

The government expects this model to support easier access and continuity of care. The article does not give a specific amount for possible savings, so the exact financial effect is not stated. It does make clear that reducing travel should relieve families and help patients remain on treatment more reliably.

The Additional Chief Secretary (Health) has been entrusted with coordinating the new Risdiplam programme. This official will help organise the expansion from the current limited arrangement to a district-wide system. The announcement was made by Health Minister K. Muraleedharan.

The medicine is expected to be supplied through the Paediatrics departments of all Medical colleges. This gives families a clear local department for receiving treatment. It also places delivery within existing government medical institutions, rather than requiring every family to attend one of only two SMA clinics.

At present, free Risdiplam is distributed through SMA clinics at the Thiruvananthapuram and Kozhikode Government Medical colleges. The new coordination structure is intended to support decentralised access and continuity of care. The government also wants the model to develop into a family-centred system that could eventually help people with other rare diseases and children with chronic illnesses.

Free Risdiplam is currently available only to patients up to 12 years of age. The government has initiated steps to remove this restriction. If completed, the benefit would extend to all eligible patients, regardless of whether they are children, adolescents, or adults.

The proposed change would mean that eligibility is no longer stopped solely because a patient passes the current age threshold. For example, an eligible SMA patient older than 12 could receive the same free medication benefit under the planned policy. The article does not state when the change will take effect or describe any revised eligibility process.

This proposal accompanies the wider distribution reform. The government plans to provide Risdiplam through Paediatrics departments in Medical colleges across all districts. Together, broader age eligibility and local delivery could make the programme more inclusive and reduce the treatment burden on families affected by SMA.

Rare diseases such as SMA often require long-term care, regular treatment, and coordination among families and health services. Ordinary short-term care is designed for a single visit or brief illness. It may not address continuing medicine needs, repeated travel, changing support needs, or the effect on caregivers. These general points come from established healthcare knowledge; the article specifically highlights access and continuity.

In this case, families currently travel long distances to obtain free Risdiplam from two Government Medical colleges. A family-centred system would bring medicine through local Medical colleges, involve Paediatrics departments, and recognise the practical burden on parents. That makes care easier to continue and better aligned with family circumstances.

The government wants the SMA model to grow into a family-centred healthcare system. It says this could eventually benefit patients with other rare diseases and children with chronic illnesses. The article does not describe the full future system, so its precise design remains unstated.